Merck Agrees to Purchase Insulin Maker SmartCells

Merck & Co., the second-biggest U.S. drug company, agreed to pay as much as $500 million for closely held SmartCells Inc., maker of an experimental diabetes treatment designed to better regulate insulin in the blood.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.